Key result
Enzyme-responsive nanoparticles preferentially deliver MMP inhibitor PD166793 to infarcted myocardium via protease and esterase action.
Why the study?
Does targeted delivery of the MMP inhibitor PD166793 via enzyme-responsive nanoparticles improve retention and MMP inhibition in the infarcted heart?
Does targeted delivery of the MMP inhibitor PD166793 via enzyme-responsive nanoparticles improve retention and MMP inhibition in the infarcted heart?
Enzyme-responsive nanoparticles offer a promising targeted delivery platform for small molecule therapeutics to the heart post-myocardial infarction.
Supports targeted delivery in rodent MI models; leaves open translation to larger species and clinical use.
In this paper, we describe block copolymer amphiphiles consisting of a hydrophilic matrix metalloproteinase (MMP) peptide substrate, and a hydrophobic small molecule MMP inhibitor PD166793 for the treatment of acute myocardial infarction. These resulting drug loaded peptide-polymer amphiphiles (PPAs) assemble in aqueous solution to yield drug loaded micellar nanoparticles. Following minimally invasive intravenous injection, these nanoparticles preferentially exit the vasculature and are physically trapped at the infarcted region of the heart due to MMP-induced peptide cleavage and aggregation. This MMP directed active assembly prevents the material from leaking out into the blood stream, enabling long-term retention. Further, we show that the conjugated MMP inhibitor (PD166793) is inactivated in the core of the micelles and can be released upon the action of proteases and esterases, leading to MMP inhibition. This work establishes a promising targeted nanoparticle platform for delivering small molecule therapeutics to the heart.
No takes yet. Share an insight, caveat, or question.
Sullivan et al. (2022) studied acute myocardial infarction. drug loaded peptide-polymer amphiphiles (PPAs) with MMP inhibitor PD166793 was evaluated. Enzyme-responsive nanoparticles loaded with the MMP inhibitor PD166793 preferentially accumulated in the infarcted heart region and released the inhibitor upon protease and esterase action.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: